Key takeaways
Sermorelin is a peptide that, though not FDA approved for this purpose, may be prescribed off label for weight loss.
Existing research on sermorelin for weight loss is limited, but possible benefits other similar medications have shown include reduced belly fat, improved muscle mass, and a small metabolism boost.
Common side effects include injection site reactions, flushing, headaches, and nausea.
Here's what we'll cover
Here's what we'll cover
Here's what we'll cover
Key takeaways
Sermorelin is a peptide that, though not FDA approved for this purpose, may be prescribed off label for weight loss.
Existing research on sermorelin for weight loss is limited, but possible benefits other similar medications have shown include reduced belly fat, improved muscle mass, and a small metabolism boost.
Common side effects include injection site reactions, flushing, headaches, and nausea.
If you’ve been looking into medical options for weight loss, you may have come across sermorelin. The injectable peptide is sometimes touted for fat loss and muscle building, but does it really work? The short answer: Taking sermorelin for weight loss may have some benefits, but a whole lot more research is needed before we can definitively say yes.
What is sermorelin?
Sermorelin is a synthetic peptide that tells the pituitary gland to release more of the body's own growth hormone (GH). This makes it a growth hormone–releasing hormone (GHRH) analog. So, rather than supplementing the body directly with more GH, sermorelin helps the body make more of it naturally.
Levels of growth hormone decrease with age, and some research suggests replacing it may help reduce body fat and increase muscle. That being said, growth hormone provides the most meaningful benefits in people who have a true growth hormone deficiency.
Does sermorelin work for weight loss?
It might. In a small study of 10 postmenopausal women, taking a GHRH analog (not quite sermorelin, but the full-length version of the molecule sermorelin is based on) led to a 16% reduction in belly fat in just three months. Another study using a different GHRH analog found it led to both significant gains in lean body mass and reductions in body fat, particularly around the belly.
That said, research on growth-hormone-boosting therapies and weight loss has been mixed, and not every study has found weight loss benefits.
Overall, the current state of research regarding sermorelin for weight loss is quite limited. Significantly more research is needed — with both more participants and focusing on sermorelin specifically — before we can draw any firm conclusions.
If you are considering sermorelin for weight loss, it is important to keep expectations realistic, says Fernando Ovalle Jr., MD, obesity medicine specialist and expert contributor and reviewer for Drugwatch.com. "In my experience, if weight loss occurs, it's usually incremental rather than dramatic.
How can sermorelin work for weight loss?
Many of the ways sermorelin may work for weight loss are indirect. It may improve body composition, energy levels, recovery, sleep quality, and exercise tolerance, Dr. Ovalle says. These gains may be more pronounced in people who have lower growth hormone levels to begin with.
Belly fat reduction
Even though the studies done thus far have been performed on GHRH-based therapies rather than sermorelin specifically, , more than one have found that these treatments can reduce body fat.
“Most clinical experience puts the fat loss at around 3% to 6% of body fat over 12–16 weeks, but what makes that number meaningful is that patients are typically gaining lean muscle at the same time,” says Shannon Arora, MD, family medicine hospitalist and Chief Medical Officer at Arora Health.
Sermorelin's potential effects on body fat may be traced back to growth hormone, Dr. Arora says. Growth hormone helps regulate the body's fat storage, especially around the midsection. "Fat loss people experience on GHRH-based therapies like sermorelin is a side effect of restoring a hormone that naturally declines with age," she says.
Improved muscle performance and recovery
A 2018 review found that growth hormone secretagogues in general (the class of drugs sermorelin belongs to) improve muscle mass. For example, studies of GH secretagogues in older adults have found that six months of treatment can lead to significant gains in lower body strength.
Additionally, people who take GHRH secretagogues like sermorelin commonly report faster workout recovery and better muscle tone, Dr. Arora says.
Together, these effects may make it easier to build muscle when exercising. And more muscle usually means a faster metabolism, which can further support weight loss efforts.
A small metabolism boost
Preserving muscle mass is important when losing weight. Doing so helps maintain a person's resting metabolic rate (RMR), which represents how many calories the body burns at rest, and may even help increase it. That means more calories may be burned, reducing the risk of weight gain.
By increasing natural growth hormone levels, sermorelin may (again, more research is needed) help boost muscle mass and metabolism, potentially helping tone the body and burn more calories.
Better sleep quality
If you are wondering what sleep has to do with weight loss, the answer is a lot. People who sleep better tend to lose more weight and fat than people who do not sleep well, according to research on weight loss programs.
Now back to sermorelin: Dr. Arora says better sleep is one of the first effects people notice after starting sermorelin, often within the first couple of weeks. “Growth hormone secretion is closely tied to deep slow-wave sleep, and restoring that signaling tends to improve sleep quality in a way that has downstream effects on energy, mood, and recovery.”
More data is needed from clinical trials to confirm whether sermorelin reliably improves sleep in practice. If sermorelin is capable of improving sleep, it may have major benefits for weight management.
Improved mood and energy levels
We all know how hard it is to work out when we feel down. That is another way sermorelin may help support a weight loss journey — by lifting mood. "There is research showing that 20 weeks of GHRH supplementation increased GABA activity in the brain, which is relevant to mood regulation and reducing anxiety," Dr. Arora says.
And if a person is sleeping better thanks to sermorelin, that may also help improve mood and energy levels, Dr. Arora says. When people feel better, they may feel more motivated to stick to their weight loss goals. They might also feel like they have more control over their emotions and be better able to avoid emotional eating, research suggests.
It’s important to keep in mind that the potential connection of sermorelin improving mood, which may then support weight loss, is based on reasonable science but still needs to be demonstrated in clinical studies of sermorelin. As more research comes out, our understanding of sermorelin will continue to improve.
Is sermorelin safe for weight loss (or in general)?
Sermorelin is generally considered safe, but the existing research is limited. The side effects are usually mild, with injection site reactions being the most common.
Sermorelin side effects and risks
Sermorelin side effects may include:
Injection site reactions
Headache
Flushing
Nausea
Water retention
Joint pain and muscle stiffness
Carpal tunnel syndrome
Changes in blood sugar regulation
"The more clinically important consideration is that sermorelin can modestly reduce insulin sensitivity, so anyone with diabetes or blood sugar concerns needs closer monitoring," Dr. Arora says. To help ensure sermorelin is safe, it is important to share a full health history and any current medications or supplements with a healthcare provider. Longer-term safety data are needed for a better understanding of sermorelin’s safety profile over time.
What is the sermorelin dosage for weight loss?
Because sermorelin has not been approved for weight loss by the US Food and Drug Administration (FDA), there is no standardized dosing and no published clinical trial has established a dose yet either. A typical range in research and clinical practice is 200–500 mcg, injected subcutaneously, typically in the evening, Dr. Arora says based on her clinical experience.
Dr. Arora says this timing is intentional. “Most of the body's growth hormone is released during deep sleep, so dosing at night aligns with that natural pulse,” she says.
Key considerations when it comes to sermorelin for weight loss
Both Drs. Ovalle and Arora caution that the first thing to know about sermorelin for weight loss is that sermorelin is not FDA-approved for obesity. Sermorelin was originally FDA-approved for growth hormone deficiency in children, but is no longer on the market. So, the only way to get it today is through an off-label prescription at a compounding pharmacy.
“This is not unusual in hormone medicine,” Dr. Arora says, “but it does mean the provider you work with needs to actually understand the literature and monitor appropriately.”
Also, Dr. Arora says, sermorelin works best when paired with a healthy diet and exercise routine. “Every study showing meaningful body composition results involved patients who were exercising and eating reasonably,” she says. “Sermorelin supports that process. It does not replace it.”
As an unapproved medication with limited research, sermorelin weight loss results are generally modest and unpredictable, Dr. Ovalle says. "Sermorelin fits more into the niche of peptide wellness or hormone optimization than evidence-based obesity medicine. The data is nowhere near as strong as what we have for medications like semaglutide or tirzepatide."
Alternatives to sermorelin for weight loss
Speaking of semaglutide and tirzepatide, there are several evidence-backed weight loss methods, including oral and injectable GLP-1 medications, other weight loss pills, and lifestyle changes.
GLP-1 injections
The FDA has approved three GLP-1 weight loss injections:
Of these, Zepbound produces the most weight loss — up to 20.9% at 72 weeks with the highest dose. In the same timeframe, Wegovy produced about 14.9% and Saxenda about 8.0% weight loss on average.
GLP-1 pills
The FDA has also approved two oral GLP-1s for weight loss. These include:
Foundayo (orforglipron), which produces an average weight loss of 7.5%–11.2% in 72 weeks, depending on the dose.
Wegovy pill (semaglutide), which produces an average weight loss of 13.6% in 64 weeks.
Other weight loss pills
Finally, the FDA has also approved several non-GLP-1 prescription weight loss pills. These include:
Qsymia (phentermine-topiramate), which produces up to 10.9% weight loss, on average, in 56 weeks.
Contrave (naltrexone/bupropion), which produces an average weight loss of about 6% in 56 weeks.
Xenical (orlistat), which produces an average weight loss of about 3.1% greater than placebo.
Xenical’s active ingredient, orlistat, is also available in lower strengths as over-the-counter Alli.
Lifestyle changes
Lifestyle changes are often recommended, even when taking weight loss medications. That is because pairing a weight loss medication with a healthy diet, regular exercise routine, and other health-focused changes can lead to significantly more weight loss than simply taking the medication.
Achieve a calorie deficit. Translation: start eating less than you used to. Experts usually recommend starting with 500 fewer calories daily, although your healthcare provider can recommend a specific number.
Exercise regularly. Aim for at least 150 minutes of moderate-intensity exercise and two resistance-based workouts weekly.
Set weight loss goals. Research suggests setting achievable goals — and then meeting them early on — sets you up for more overall weight loss. So start small, be specific, and set new goals as you meet your previous ones.
Bottom line
Sermorelin may have some metabolic benefits, but more research is needed before it becomes the next big thing for weight loss. Here is what to remember:
Sermorelin is a synthetic, injectable peptide that works by telling the pituitary gland to release more growth hormone.
The research, while limited, suggests that sermorelin could help by boosting muscle gains, reducing belly fat, and improving metabolism.
Common side effects of sermorelin include injection site reactions, nausea, headaches, facial flushing, and carpal tunnel syndrome.
Today, sermorelin is not FDA-approved for weight loss, and can only be accessed through a compounding pharmacy.
Other FDA-approved, evidence-backed options for weight loss include oral and injectable GLP-1s and weight loss pills.
Frequently asked questions (FAQs)
How much weight can you lose on sermorelin?
How quickly does sermorelin work?
Most studies of sermorelin report body fat losses within three to six months.
Is sermorelin the same as Ozempic?
No, sermorelin is not the same as Ozempic (semaglutide). Although both injections may be prescribed off-label for weight loss, they work through different mechanisms. Sermorelin stimulates the release of growth hormone, while Ozempic mimics a gut hormone called GLP-1 that regulates appetite and blood sugar. Ozempic is FDA-approved for type 2 diabetes.
DISCLAIMER
If you have any medical questions or concerns, please talk to your healthcare provider. The articles on Health Guide are underpinned by peer-reviewed research and information drawn from medical societies and governmental agencies. However, they are not a substitute for professional medical advice, diagnosis, or treatment.
Zepbound Important Safety Information: Read more about serious warnings and safety info.
Wegovy Important Safety Information: Read more about serious warnings and safety info.
Saxenda Important Safety Information: Read more about serious warnings and safety info.
Foundayo Important Safety Information: Read more about serious warnings and safety info.
Ozempic Important Safety Information: Read more about serious warnings and safety info.
References
Cava, E., Yeat, N. C., & Mittendorfer, B. (2017). Preserving Healthy Muscle during Weight Loss. Advances in Nutrition, 8(3), 511–519. doi: 10.3945/an.116.014506. Retrieved from https://pubmed.ncbi.nlm.nih.gov/28507015/
Chao, A. M., Tronieri, J. S., Alamuddin, N., et al. (2026). Behavioral Approaches to Obesity Management. Endotext. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK278952/
Elmaleh-Sachs, A., Schwartz, J. L., Bramante, C. T., et al. (2023). Obesity Management in Adults: A Review. JAMA, 330(20), 2000–2015. doi: 10.1001/jama.2023.19897. Retrieved from https://jamanetwork.com/journals/jama/article-abstract/2812316?
Friedman, S. D., Baker, L. D., Borson, S., et al. (2013). Growth Hormone–Releasing hormone effects on brain Γ-Aminobutyric acid levels in mild cognitive impairment and healthy aging. JAMA Neurology, 70(7), 883. doi: 10.1001/jamaneurol.2013.1425. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC3764915/
Gasoyan, H., Pfoh, E. R., Schulte, R., et al. (2024). One-Year weight reduction with semaglutide or liraglutide in clinical practice. JAMA Network Open, 7(9), e2433326. doi: 10.1001/jamanetworkopen.2024.33326. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11400221/
Gitsi, E., Kokkinos, A., Konstantinidou, S. K., et al. (2024). The Relationship between Resting Metabolic Rate and Body Composition in People Living with Overweight and Obesity. Journal of Clinical Medicine, 13(19), 5862. doi: 10.3390/jcm13195862. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11477793/
Grave, R. D. (2024). The benefit of healthy lifestyle in the era of new medications to treat obesity. Diabetes Metabolic Syndrome and Obesity, 17, 227–230. doi: 10.2147/dmso.s447582. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC10798050/
Gudzune, K. A. & Kushner, R. F. (2024). Medications for Obesity: A Review. JAMA, 332(7), 571–584. doi: 10.1001/jama.2024.10816. Retrieved from https://pubmed.ncbi.nlm.nih.gov/39037780/
Ingels, J. S. & Zizzi, S. (2018). A qualitative analysis of the role of emotions in different patterns of long-term weight loss. Psychology and Health, 33(8), 1014–1027. doi: 10.1080/08870446.2018.1453511. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC5964031/
Kline, C. E., Chasens, E. R., Bizhanova, Z., et al. (2021). The association between sleep health and weight change during a 12-month behavioral weight loss intervention. International Journal of Obesity, 45(3), 639–649. doi: 10.1038/s41366-020-00728-8. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC7914147/
Rodriguez, P. J., Cartwright, B. M. G., Gratzl, S., et al. (2024). Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Internal Medicine, 184(9), 1056. doi: 10.1001/jamainternmed.2024.2525. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11231910/
Santos, W. O. D., Juliano, V. a. L., Vieira, H. R., et al. (2023). SAT605 growth hormone action in somatostatin neurons regulates anxiety and fear memory. Journal of the Endocrine Society, 7(Supplement_1). doi: 10.1210/jendso/bvad114.1338. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC10554847/
Sigalos, J. T. & Pastuszak, A. W. (2017). The safety and efficacy of growth hormone secretagogues. Sexual Medicine Reviews, 6(1), 45–53. doi: 10.1016/j.sxmr.2017.02.004. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC5632578/
Sinha, D. K., Balasubramanian, A., Tatem, A. J., et al. (2020). Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology, 9(S2), S149–S159. doi: 10.21037/tau.2019.11.30. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC7108996/
Tavares, A. B. W., Micmacher, E., Biesek, S., et al. (2013). Effects of Growth Hormone Administration on Muscle Strength in Men over 50 Years Old. International Journal of Endocrinology, 2013, 1–6. doi: 10.1155/2013/942030. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC3870652/
Tchang, B. G., Aras, M., Kumar, R. B., et al. (2025). Pharmacologic Treatment of Overweight and Obesity in Adults. EndoText. Retrieved from https://www.endotext.org/chapter/pharmacologic-treatment-of-overweight-and-obesity-in-adults/
U.S. Food and Drug Administration (FDA). (2004). Search Orphan Drug Designations and Approvals. Retrieved from https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=24687
Veldhuis, J. D., Patrie, J. M., Frick, K., et al. (2005). Administration of recombinant human GHRH-1,44-amide for 3 months reduces abdominal visceral fat mass and increases physical performance measures in postmenopausal women. European Journal of Endocrinology, 153(5), 669–677. doi: 10.1530/eje.1.02019. Retrieved from https://pubmed.ncbi.nlm.nih.gov/16260425/
Weiss, E. P., Jordan, R. C., Frese, E. M., et al. (2016). Effects of weight los*s on lean mass, strength, bone, and aerobic capacity. *Medicine & Science in Sports & Exercise, 49(1), 206–217. doi: 10.1249/mss.0000000000001074. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC5161655/
Wharton, S., Aronne, L. J., Stefanski, A., et al. (2025). Orforglipron, an oral Small-Molecule GLP-1 receptor agonist for obesity treatment. New England Journal of Medicine, 393(18), 1796–1806. doi: 10.1056/nejmoa2511774. Retrieved from https://pubmed.ncbi.nlm.nih.gov/40960239/
Wharton, S., Lingvay, I., Bogdanski, P., et al. (2025). Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. New England Journal of Medicine, 393(11), 1077–1087. doi: 10.1056/nejmoa2500969. Retrieved from https://pubmed.ncbi.nlm.nih.gov/40934115/















